Preclinical studies on a low molecular weight heparin

Fareed, Jawed; Jeske, Walter; Eschenfelder, Volker; Iqbal, Omar; Hoppensteadt, Debra; Ahsan, Ahmad

doi:10.1016/0049-3848(95)00226-x

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other types of heparins are reviparin, dalteparin, tinzaparin, nadroparin, and enoxaparin. All these heparins have undergone preclinical and clinical trials, and UFH and LMWH were proven to have better results for prevention of deep vein thrombosis [31,32,33]. Also, heparin was administrated onto patients with COVID-19, and given positive results, beyond the anticoagulant effect [34].…”

Section: Heparinmentioning

confidence: 99%

Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review

Patel

2021

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Blood contacting materials are concerned with biocompatibility including thrombus formation, decrease blood coagulation time, hematology, activation of complement system, platelet aggression. Interestingly, recent research suggests that biocompatibility is increasing by incorporating various materials including heparin using different methods. Basic of heparin including uses and complications was mentioned, in which burst release of heparin is major issue. To minimize the problem of biocompatibility and unpredictable heparin release, present review article potentially reviews the reported work and investigates the various immobilization methods of heparin onto biomaterials, such as polymers, metals, and alloys. Detailed explanation of different immobilization methods through different intermediates, activation, incubation method, plasma treatment, irradiations and other methods are also discussed, in which immobilization through intermediates is the most exploitable method. In addition to biocompatibility, other required properties of biomaterials like mechanical and corrosion resistance properties that increase by attachment of heparin are reviewed and discussed in this article.

show abstract

Section: Heparinmentioning

confidence: 99%

Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review

Patel

2021

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…It is characterized by a low mean molecular weight (4 to 8 kd), which is approximately a third the molecular weight of standard heparin, and a more homogenous distribution of molecular weight. 1 Use of LMWH has several advantages with respect to pharmacokinetics and pharmacodynamics, compared with the use of unfractionated heparin. For example, LMWH has a higher bioavailability when administered subcutaneously 2,3 and a lower frequency of bleeding episodes.…”

mentioning

confidence: 99%

Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs

Mischke¹,

Grebe²,

Jacobs³

et al. 2001

ajvr

View full text Add to dashboard Cite

Heparin plasma activity was only slightly higher than that recommended for LMWH treatment of humans, and none of the dogs had signs of increased bleeding. Thus, administration of heparin in accordance with this dosing regimen can be recommended for use in clinical studies. The screening tests investigated were not suitable for use in monitoring LMWH treatment of dogs. Assays that use chromogenic substrates are necessary to reliably monitor LMWH plasma concentrations in dogs.

show abstract

“…No prior studies have addressed this question in a similar population. Studies in normal volunteers show a rapid 2-fold increase in TFPI after a dose of LMWH, with a return to baseline levels by 5-10 h, even though anti-factor Xa activity remains detectable for 18 h (15,16,(34)(35)(36). Our study does not address transient release of TFPI, but rather steady-state levels that would correlate with sustained antithrombotic effect.…”

Section: Discussionmentioning

confidence: 81%

The Effect of Unfractionated vs. Low Molecular Weight Heparin on Tissue Factor Pathway Inhibitor Levels in Hospital Inpatients

Brown

Kuter²

2001

Thromb Haemost

View full text Add to dashboard Cite

SummaryAlthough heparin is widely used as an antithrombotic agent, its multiple mechanisms of action are not fully defined. Recent work has suggested that tissue factor pathway inhibitor (TFPI) may contribute to the antithrombotic activity of heparin by inhibiting the extrinsic pathway of coagulation. We have investigated the effect of heparin on TFPI and have found that when unfractionated heparin is given by continuous intravenous infusion to hospitalized inpatients, TFPI levels increase 2.3-fold and remain high as long as heparin is continued, but return to baseline levels soon after the infusion is stopped. In contrast, therapeutic doses of the low molecular weight heparin, dalteparin, resulted in significantly less TFPI induction. Given the increasing number of studies establishing the clinical efficacy of low molecular weight heparins as antithrombotic agents, these results suggest that TFPI may not be a major contributor to the antithrombotic effect of heparin.

show abstract

Preclinical studies on a low molecular weight heparin

Cited by 11 publications

References 17 publications

Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review

Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review

Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs

The Effect of Unfractionated vs. Low Molecular Weight Heparin on Tissue Factor Pathway Inhibitor Levels in Hospital Inpatients

Contact Info

Product

Resources

About